Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial buff.ly/FuH8fhx The 10-year follow-up of the CHAARTED trial confirms that adding docetaxel to androgen deprivation therapy significantly improves overall survival in patients with high-volume metastatic hormone-sensitive prostate cancer, while PSA nadir <0.2 ng/mL at 6 months emerged as a powerful independent predictor of long-term survival across both treatment arms. Achieving this low PSA was strongly associated with better outcomes regardless of baseline prognostic factors, and docetaxel increased the likelihood of reaching this threshold, supporting the use of PSA nadir as a key marker for response assessment and potential response-adapted treatment strategies. #ProstateCancer @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @DrYukselUrun #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua